Literature DB >> 1829907

Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group)

R L Jansen1, R Sylvester, D T Sleyfer, W W ten Bokkel Huinink, S B Kaye, W G Jones, J Keizer, A T van Oosterom, S Meyer, C P Vendrik.   

Abstract

From 1979 to 1983 the EORTC GU Group treated 239 patients with disseminated non-seminomatous testicular cancer with combination chemotherapy comprising cisplatin, vinblastine and bleomycin in a prospectively controlled trial. The protocol required complete resection of residual masses after induction chemotherapy, provided that serum tumour markers were normal. 102 patients were operated on. 27 patients had mature teratoma (teratoma differentiated) in the resected specimens and 23 had viable cancer. Follow-up data were available for 26 and 22 of these patients, respectively. 23 of 26 patients (88%) with mature teratoma are alive and disease free after a follow-up of 53-110 months (median 92 months). 3 patients developed progressive disease; 1 died. A peculiar case of growing mature teratoma on the forearm is described. 13 of 22 patients (59%) with residual carcinoma are alive and disease free after a follow-up of 74-112 months (median 95 months). The prognosis of patients with carcinoma is shown to be correlated with the completeness of surgery, which in turn is correlated with the initial tumour mass before chemotherapy.

Entities:  

Mesh:

Year:  1991        PMID: 1829907     DOI: 10.1016/0277-5379(91)90168-d

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  12 in total

Review 1.  Testicular cancer and related neoplasms.

Authors:  G M Mead
Journal:  BMJ       Date:  1992-05-30

Review 2.  Testicular carcinoma.

Authors:  A O'Callaghan; G M Mead
Journal:  Postgrad Med J       Date:  1997-08       Impact factor: 2.401

3.  Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors.

Authors:  J Baniel; B J Roth; R S Foster; J P Donohue
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

4.  Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management.

Authors:  C B Wilson; H E Young; R J Ott; M A Flower; B F Cronin; B E Pratt; V R McCready; A Horwich
Journal:  Eur J Nucl Med       Date:  1995-06

5.  Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis.

Authors:  E W Steyerberg; H J Keizer; J Zwartendijk; G L Van Rijk; C J Van Groeningen; J D Habbema; G Stoter
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

6.  Prognosis after salvage treatment for unselected male patients with germ cell tumours.

Authors:  A Gerl; C Clemm; N Schmeller; R Hartenstein; R Lamerz; W Wilmanns
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

7.  Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer.

Authors:  E W Steyerberg; H J Keizer; S D Fosså; D T Sleijfer; D F Bajorin; J P Donohue; J D Habbema
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

8.  Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).

Authors:  J S de Bono; J Paul; A Simpson; A Anthoney; D Kirk; M Underwood; J Graham; S B Kaye
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

9.  Salvage treatment in male patients with germ cell tumours.

Authors:  D Josefsen; S Ous; J Høie; A E Stenwig; S D Fosså
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

10.  Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours.

Authors:  A Gerl; C Clemm; N Schmeller; H Dienemann; M Weiss; M Kriegmair; U Löhrs; W Wilmanns
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.